Cancer rarely comes to mind when most people think of vaccines, but that appears to be changing.
TapImmune, an immuno-oncology company in Florida is currently clinically testing a vaccine specifically for triple-negative breast and ovarian cancer.
A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer (TNBC).
TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.
Precision Vaccination highlighted our cancer vaccine, TPIV200 for treating triple-negative breast cancer.
Peter Hoang, President and CEO of TapImmune, is enthusiastic about a cancer vaccine under development by TapImmune that could help prevent recurrence of such cancers in women.
With new innovations and breakthroughs in the field of immunotherapy TapImmune CEO & President, Peter Hoang has been amazed by the change of pace within the field.
TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.
TPIV 200 is a vaccine that the immuno-oncology company TapImmune is developing as a treatment for platinum-chemotherapy resistant ovarian cancer or triple-negative breast cancer.
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.